The Goldman Sachs Group Increases Twist Bioscience (NASDAQ:TWST) Price Target to $55.00

Twist Bioscience (NASDAQ:TWST) had its price objective boosted by The Goldman Sachs Group from $45.00 to $55.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

TWST has been the topic of a number of other reports. TD Cowen increased their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company a buy rating in a research report on Thursday, June 13th. Evercore ISI increased their price objective on Twist Bioscience from $46.00 to $50.00 and gave the company an outperform rating in a research report on Friday, May 3rd. Guggenheim began coverage on Twist Bioscience in a research report on Tuesday, June 4th. They issued a buy rating and a $53.00 price target on the stock. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an outperform rating in a research report on Friday, May 3rd. Finally, Scotiabank raised their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a research report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $49.75.

Twist Bioscience Trading Up 2.9 %

Shares of TWST opened at $52.48 on Tuesday. The business’s fifty day moving average price is $47.08 and its two-hundred day moving average price is $39.20. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $55.26.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period last year, the company earned ($1.06) EPS. Research analysts anticipate that Twist Bioscience will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider William Banyai sold 798 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the sale, the insider now owns 345,188 shares of the company’s stock, valued at approximately $12,816,830.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at approximately $5,307,324.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Banyai sold 798 shares of Twist Bioscience stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $29,629.74. Following the completion of the sale, the insider now directly owns 345,188 shares in the company, valued at approximately $12,816,830.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 19,570 shares of company stock valued at $827,162. 3.92% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. raised its stake in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares during the period. CWM LLC raised its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the period. D.A. Davidson & CO. raised its stake in shares of Twist Bioscience by 3.4% in the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after purchasing an additional 554 shares during the period. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at about $30,000. Finally, Swiss National Bank raised its stake in shares of Twist Bioscience by 0.8% in the 1st quarter. Swiss National Bank now owns 114,000 shares of the company’s stock valued at $3,911,000 after purchasing an additional 900 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.